Research programme: vaccines - Capo Therapeutics

Drug Profile

Research programme: vaccines - Capo Therapeutics

Alternative Names: Anti-Aβ vaccine - Capo Therapeutics; Anti-tau vaccine - Capo Therapeutics; Anti-β amyloid vaccine - Capo Therapeutics; AV 1950D; AV-1947D; AV-1948D; AV-1949D; AV-1950R; AV-1959D; AV-1959R; AV-1960CP; AV-1980D; AV-1980R; AV-1991CP; AV-1992CP

Latest Information Update: 10 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Flinders University; University of California at Irvine
  • Developer Capo Therapeutics
  • Class Vaccines
  • Mechanism of Action Amyloid beta-protein modulators; Immunostimulants; Tau protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 05 Jul 2016 Capo Therapeutics in-licenses vaccines against Alzheimer's disease from Flinders University and University of California
  • 05 Jul 2016 Preclinical trials in Alzheimer's disease in USA (Parenteral)
  • 05 Jul 2016 Preclinical trials in Parkinson's disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top